Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on LinkedIn:
“On Friday, the FDA approved rusfertide, the first-in-class hepcidin mimetic for the treatment of erythrocytosis in adults with polycythemia vera (PV).
What makes this approval particularly interesting is the biology. Although erythrocytosis in PV is driven by constitutive JAK2 signaling, erythropoiesis remains dependent on iron.
Rusfertide mimics the activity of hepcidin, targeting ferroportin and restricting the movement of iron into the circulation.
The resulting reduction in iron availability for erythropoiesis provides a fundamentally different way to control hematocrit, one based on regulating iron trafficking rather than directly suppressing the malignant clone.
In the phase 3 VERIFY trial, which enrolled 293 patients requiring frequent phlebotomy despite standard-of-care therapy, 76.9% of patients receiving rusfertide avoided meeting criteria for phlebotomy during weeks 20–32, compared with 32.9% receiving placebo. Treatment also reduced phlebotomy burden and improved hematocrit control.
For patients living with PV and the cumulative burden of repeated phlebotomy, this creates an entirely new therapeutic axis.
It is also an elegant example of translational hematology: understanding the physiology that sustains a malignant phenotype can identify therapeutic vulnerabilities downstream of the initiating mutation.
Important questions remain, including how rusfertide will be integrated with cytoreductive therapies and, importantly, whether improved hematocrit control via this mechanism ultimately translates into reductions in thrombosis or changes in disease trajectory.
Those outcomes have not yet been established.
Nevertheless, this is a meaningful advance for patients with polycythemia vera and a fascinating validation of the hepcidin–ferroportin axis as a therapeutic target.”
Other posts featuring Nathan Connel on Hemostasis Today.
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
-
Sep 3, 2026, 01:03SHOT Urges Safe Component Matching While NHSBT Appeals for Black Donors
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden
-
Sep 3, 2026, 00:44Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal
-
Sep 3, 2026, 00:33Hannah Isles: Interesting Link between Aging, Serotonin, Platelets and COVID-19 Severity
-
Sep 3, 2026, 00:22Danny Hsu: Paradigm Shift in PE Management? – Unpacking the PRAGUE-26 Trial
-
Sep 3, 2026, 00:14Leonardo Roever: Antiphospholipid Antibodies Present in 19% of Ischemic Stroke Cases
-
Sep 3, 2026, 00:03Jochebed Adwoa Sutherland: First Reported Case of Breast Mondor’s Disease in a Patient Living with Sickle Cell